[analyse_image type=”featured” src=”https://images.euronews.com/articles/stories/09/98/61/66/1200x675_cmsv2_95977e3d-a11c-5229-b2cb-97f92f10d30d-9986166.jpg”]

Turkey steel plant blast kills at least 17

Robots, AI agents and a Nvidia probe: Web Summit 2026 Opens in Lisbon

Pope Leo XIV urges Milei’s government to protect the most vulnerable

Storm Charles to hit Portugal and Spain with torrential rain and 120 km/h winds
US drug watchdog orders new safety warnings for weight-loss drugs over potential risk of vision loss

The FDA’s assessment included an analysis of 126 clinical trials involving over 134,000 patients.
– Copyright Copyright 2020 The Associated Press. All rights reserved.
The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines to update their safety labels to warn of a potential increased risk of a rare but serious eye condition that can cause permanent vision loss.
The US drug watchdog FDA on Monday said the weight-loss drugs had been associated with non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can lead to sudden, painless loss of vision in one eye, including permanent vision loss.
The new warning requirements cover all GLP-1 receptor agonists, a class of medicines widely used to treat type 2 diabetes and obesity. They include popular treatments such as Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as other medicines in the class.
The FDA’s assessment included an analysis of 126 clinical trials involving over 134,000 patients. The agency also reviewed real-world data and published observational studies. While it acknowledged limitations in the available evidence, it concluded that a potential increased risk warranted additional warnings across the drug class.
The move adds to the safety scrutiny surrounding a rapidly expanding class of medicines that has become central to the treatment of obesity and type 2 diabetes.
Last year, Europe’s medicines watchdog (EMA) determined that NAION should be classified as a very rare side effect of semaglutide, the active ingredient of some weight-loss medicines, affecting up to one in 10,000 patients.
Go to accessibility shortcuts
Read more

Health gets just a small fraction of climate finance

Climate crisis now a health emergency of ‘pandemic scale’, UN warns

Russia: HIV epidemic in 27 regions, epidemiologists say

Health gets just a small fraction of climate finance

Climate crisis now a health emergency of ‘pandemic scale’, UN warns

Russia: HIV epidemic in 27 regions, epidemiologists say

Health gets just a small fraction of climate finance

Climate crisis now a health emergency of ‘pandemic scale’, UN warns

When antibiotics stop working: Europe’s growing superbug threat

Russia: HIV epidemic in 27 regions, epidemiologists say

US measles cases exceed 5,000, hitting a 35-year high in 2026
COVID: Should we fear a new winter wave?
Scientists discover first new antibiotics in over 60 years using AI
WHO backs trials for two new vaccines against Ebola outbreak
When antibiotics stop working: Europe’s growing superbug threat
Scientists develop first-ever “broad-spectrum” bird flu jab using AI
[analyse_source url=”https://www.euronews.com/2026/11/09/us-drug-watchdog-orders-new-safety-warnings-for-weight-loss-drugs-over-potential-risk-of-v”]